| 摘要 |
FIELD: medicine. ^ SUBSTANCE: group of inventions refers to medicine, particularly to immunology, and concerns treatment of rheumatoid arthritis associated with inadequate response to TNF-alpha inhibitor. The treatment is ensured by intravenous introduction of antibodies bound with CD20, particularly humanised 2H7v16, containing variable domains presented with SEQ ID Nos. 1 and 2. Antibodies are injected intravenously in dosage 1000 mg twice. ^ EFFECT: effective treatment of arthritis associated with inadequate response to TNF-alpha inhibitor due to introduction regimen developed by the applicant, extension of range of medical products for treatment of said pathology. ^ 2 cl, 1 tbl, 1 ex |
